BR112017025872A2 - proteínas de ligação multiespecíficas - Google Patents
proteínas de ligação multiespecíficasInfo
- Publication number
- BR112017025872A2 BR112017025872A2 BR112017025872A BR112017025872A BR112017025872A2 BR 112017025872 A2 BR112017025872 A2 BR 112017025872A2 BR 112017025872 A BR112017025872 A BR 112017025872A BR 112017025872 A BR112017025872 A BR 112017025872A BR 112017025872 A2 BR112017025872 A2 BR 112017025872A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding proteins
- multispecific binding
- proteins
- relates
- multispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186423P | 2015-06-30 | 2015-06-30 | |
PCT/US2016/040007 WO2017004149A1 (en) | 2015-06-30 | 2016-06-29 | Multi-specific binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017025872A2 true BR112017025872A2 (pt) | 2018-08-14 |
Family
ID=56409233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017025872A BR112017025872A2 (pt) | 2015-06-30 | 2016-06-29 | proteínas de ligação multiespecíficas |
Country Status (14)
Country | Link |
---|---|
US (1) | US20170002097A1 (pt) |
EP (1) | EP3317299A1 (pt) |
JP (2) | JP2018519832A (pt) |
KR (1) | KR20180021875A (pt) |
CN (1) | CN107949570A (pt) |
AU (1) | AU2016285858A1 (pt) |
BR (1) | BR112017025872A2 (pt) |
CA (1) | CA2986066A1 (pt) |
CL (1) | CL2017003311A1 (pt) |
EA (1) | EA201890177A1 (pt) |
IL (1) | IL256298A (pt) |
MX (1) | MX2017016842A (pt) |
PH (1) | PH12017502277A1 (pt) |
WO (1) | WO2017004149A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
TW202016151A (zh) * | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
BR112021024112A2 (pt) | 2019-06-04 | 2022-03-22 | Jiangsu Hengrui Medicine Co | Anticorpo capaz de se ligar à linfopoietina estromal tímica e uso do mesmo |
WO2022154762A1 (en) * | 2021-01-18 | 2022-07-21 | Turgut İlaçlari A.Ş. | Method of producing adalimumab |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL376536A1 (pl) * | 2002-08-28 | 2006-01-09 | Immunex Corporation | Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego |
US20070274985A1 (en) * | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
CN102448985B (zh) * | 2009-05-27 | 2015-08-05 | 霍夫曼-拉罗奇有限公司 | 三或四特异性抗体 |
TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
DK2794905T3 (da) * | 2011-12-20 | 2020-07-06 | Medimmune Llc | Modificerede polypeptider til bispecifikke antistofgrundstrukturer |
WO2013177101A2 (en) * | 2012-05-22 | 2013-11-28 | Bristol-Myers Squibb Company | Bispecific antibodies and methods of using the same |
AU2013293092A1 (en) * | 2012-07-23 | 2015-02-26 | Zymeworks Inc. | Immunoglobulin constructs comprising selective pairing of the light and heavy chains |
AU2013352812B2 (en) * | 2012-11-27 | 2019-06-20 | Ajou University Industry-Academic Cooperation Foundation | CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2016
- 2016-06-29 CA CA2986066A patent/CA2986066A1/en not_active Abandoned
- 2016-06-29 KR KR1020187002753A patent/KR20180021875A/ko not_active Application Discontinuation
- 2016-06-29 BR BR112017025872A patent/BR112017025872A2/pt not_active IP Right Cessation
- 2016-06-29 MX MX2017016842A patent/MX2017016842A/es unknown
- 2016-06-29 EA EA201890177A patent/EA201890177A1/ru unknown
- 2016-06-29 EP EP16738339.7A patent/EP3317299A1/en not_active Withdrawn
- 2016-06-29 JP JP2017568276A patent/JP2018519832A/ja active Pending
- 2016-06-29 WO PCT/US2016/040007 patent/WO2017004149A1/en active Application Filing
- 2016-06-29 CN CN201680050365.2A patent/CN107949570A/zh active Pending
- 2016-06-29 AU AU2016285858A patent/AU2016285858A1/en not_active Abandoned
- 2016-06-29 US US15/196,694 patent/US20170002097A1/en not_active Abandoned
-
2017
- 2017-12-11 PH PH12017502277A patent/PH12017502277A1/en unknown
- 2017-12-13 IL IL256298A patent/IL256298A/en unknown
- 2017-12-21 CL CL2017003311A patent/CL2017003311A1/es unknown
-
2021
- 2021-05-13 JP JP2021081888A patent/JP2021119788A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170002097A1 (en) | 2017-01-05 |
CL2017003311A1 (es) | 2018-06-15 |
PH12017502277A1 (en) | 2018-06-11 |
AU2016285858A1 (en) | 2017-11-30 |
JP2021119788A (ja) | 2021-08-19 |
KR20180021875A (ko) | 2018-03-05 |
IL256298A (en) | 2018-02-28 |
WO2017004149A1 (en) | 2017-01-05 |
CA2986066A1 (en) | 2017-01-05 |
MX2017016842A (es) | 2018-04-24 |
EA201890177A1 (ru) | 2018-06-29 |
CN107949570A (zh) | 2018-04-20 |
JP2018519832A (ja) | 2018-07-26 |
EP3317299A1 (en) | 2018-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501159A1 (en) | Composition and methods for immunooncology | |
HK1253065A1 (zh) | 靶向蛋白質的化合物、其組合物、方法和用途 | |
EA201890493A1 (ru) | РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ | |
WO2018109170A3 (en) | Il-11ra antibodies | |
BR112017003414A2 (pt) | composições compreendendo caseína e métodos para produzir as mesmas | |
EA201891211A1 (ru) | Ингибиторы cxcr2 | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
EA201992232A1 (ru) | Композиции и способы для иммуноонкологии | |
CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
BR112017025872A2 (pt) | proteínas de ligação multiespecíficas | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
GEP201706760B (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
CY1120997T1 (el) | Πρωτεϊνες συντηξης uti | |
MX2019010492A (es) | Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado. | |
MX2018003678A (es) | Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion. | |
MX2018005785A (es) | Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos. | |
EP3313393A4 (en) | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | |
EP3300501A4 (en) | NOVEL COMPOSITIONS, USES THEREOF AND PREPARATION METHODS | |
MX2017009180A (es) | Biomateriales de nanocelulosa sintetizada bacterialmente y de fases múltiples, y método para producirlos. | |
BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
EA201791716A1 (ru) | Фармацевтический состав |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2729 DE 25-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |